Compare Amphastar Pharmaceuticals Inc (AMPH) vs Wahed FTSE USA Shariah ETF (HLAL) Price & Performance

AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.

The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.

HLAL trades at $72.05, up 0.67% with a bullish technical signal from moving averages. The stock shows neutral momentum oscillators with key support at $71 and resistance at $72. Financial ratios remain undisclosed in current data, requiring deeper fundamental analysis.

The bullish technical setup suggests potential upside if resistance breaks, but limited fundamental data warrants caution. Investors should await earnings reports and valuation metrics for clearer investment thesis development amid current information gaps.